Glythera makes Significant Appointments to Support Company Expansion

Glythera Set to Benefit From Nigel Burns and Ian Evetts Strategic Biotherapeutics Experience

Newcastle-Upon-Tyne, UK (2 April, 2014) – Glythera, a biotechnology company specializing in the development of next generation bio-therapeutics, including Antibody Drug Conjugates, through the application of its proprietary linker and stable glycan technologies PermaLink™ and PermaCarb™, is pleased to announce the appointment of Nigel Burns as Non-Executive Director and Ian Evetts as Commercial Director. Glythera has recently validated data from their core technologies and the addition of Burns and Evetts coincides with the company’s expansion plan exploring new opportunities to provide essential support during the company’s growth plan.

Nigel Burns brings over 25 years experience in the Biopharmaceuticals and Biotechnology industry to Glythera. He has extensive experience leading product management and has held a series of leadership roles including, Senior Vice President of Cambridge Antibody Technology, Non-Executive Director of Navion, Chairman of Cell Medica, Director and Founder of Nascient and most recently, CEO and Founder of SweetSpot Therapeutics Ltd. As Non-Executive Director, Dr Burns will support the development of Glythera’s technology and future business strategies, bringing new levels of focus and innovation to the company’s offerings.

Nigel Burns said of his appointment,

"I’m very excited to take on this new role at Glythera at such an important time in the company’s development. Glythera is positioned as a key player in the emerging drug therapies market and I’m delighted to join the team and look forward to helping to develop new strategies and drive the future of Glythera’s technologies and therapies."

Ian Evetts joins Glythera with over 20 years experience in the Pharmaceutical industry. He has a track record of senior strategic and operational roles including, Managing Director at Atebion BDS Ltd, Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies, a key growth area for Glythera.

Commenting on his appointment, Ian Evetts said,

"Glythera is an innovative biotechnology company and their proprietary linker and stable glycan technologies represent a leap forward in the development of next generation therapies. I am extremely pleased to be involved at this exciting time for the company and I look forward to working with the team as it continues to expand and maximise new opportunities."

Dr. Anthony Baxter, Chairman of Glythera, welcomed the new members of the team,

"We are delighted that Ian and Nigel have joined our team. Their in-depth knowledge of large Pharma processes and needs, combined with an undisputed understanding of the relevant biotechnology science will be invaluable to us, particularly as we grow and drive the technologies and therapies business forward."

For further information about Glythera’s leadership team and its linker and stable glycan technologies, please visit or email: [email protected].